# Major non-COVID vaccine narratives: editorial research

**As of 14 October 2026. Report only.** This is a claim-led map, not a recommendation to create one page per vaccine. It concentrates on measles/MMR, HPV, influenza, hepatitis B and polio; RSV is a watch item. Scientific findings, prominence, and editorial priority are separate judgments. No posting, publishing or outreach was performed.

## Results and recommended decisions

1. **Highest-priority update: existing measles/MMR coverage.** Add disease-severity comparisons, vitamin A's genuine treatment role and its limits as prevention, and the distinction between vaccine-strain detection and wild-virus outbreaks. Do not create another MMR/autism page. Prominence is supported by representative US surveys plus 2025–2026 original publications; vitamin A has a separate attention signal.
2. **Strong standalone candidate: “Does the HPV vaccine cause infertility?”** The recurring infertility/sterilization narrative is documented across several vaccine-introduction settings, including 2026 Sierra Leone. Include cancer prevention and a short sexual-behavior section. Do not infer worldwide or US belief prevalence from African social listening or Pakistani examples.
3. **Strong standalone candidate: “Why vaccinate newborns against hepatitis B?”** Distinguish the false premise that infants cannot acquire a sexually transmitted infection from legitimate disagreement about universal versus targeted birth dosing. The current US schedule needs unusually careful dating because a court stay superseded widely circulated 2025–2026 policy announcements.
4. **One influenza evidence page, or a substantial section in existing vaccine-effectiveness coverage.** Separate “the shot infects you with flu” from “vaccinated people had more positive tests in one study.” The Cleveland Clinic result exists and should be explained, not denied. Recent recurrence is documented, but a current representative prevalence estimate for the precise causal claim was not found.
5. **Conditional standalone: “Can polio vaccines cause polio?”** A simple false verdict would itself misinform. Oral vaccine-associated paralysis and circulating vaccine-derived poliovirus are real; injectable IPV cannot cause poliovirus infection. A good page must explain formulation, setting, transmission and why outbreaks can persist despite eradication successes.
6. **RSV: watch/real-risk section, not a misinformation standalone yet.** Genuine safety signals deserve acknowledgment. The evidence found does not establish broad current prevalence of a specific false RSV claim. Infant monoclonal antibodies, maternal vaccination and older-adult vaccines must be kept separate.

### Priority and evidence at a glance

| Narrative family | Current/recent prominence evidence | Scientific adjudication | Editorial placement |
|---|---|---|---|
| Measles harmless; vaccine more dangerous; vitamin A alternative | Strong US survey evidence; original March 2025 and September 2026 artifacts; 2025 search-interest study published 2026 | Strong evidence against blanket harmlessness and substituting supplements; legitimate treatment and nutritional benefits must be retained | Update existing measles/MMR; vitamin A standalone only if needed for distinct search intent |
| HPV infertility/sterilization | Multiple country-specific 2025 signals and a 2026 field report; no representative cross-country prevalence established | Population evidence does not support increased infertility; uncertainty for rare outcomes is not literally zero | Standalone fertility page; behavior and cancer-benefit sections |
| Newborn hepatitis B unnecessary because only sex/drug exposure matters | High-profile September 2025 original speech; ongoing policy controversy; no representative exact false-belief item found | Infants can acquire HBV perinatally and through blood exposure; universal birth-dose design is a separate policy question | Standalone explanatory fact-check |
| Flu shot causes flu; one negative estimate proves vaccines harmful/ineffective | Historical representative belief measure; 2025 original amplification, September 2026 recurrence | Injection cannot deliver replicating influenza infection; effectiveness varies; observational negative association is real but not general causal proof | One consolidated page/section |
| Polio vaccines cause all polio / vaccination is pointless | UNICEF 2025 multilingual monitoring; WHO regional March 2026 monitoring; September 2026 original recurrence | OPV risk is real; IPV/OPV and VAPP/cVDPV distinctions essential | Nuanced standalone if site gap; avoid categorical false label |
| RSV products broadly dangerous/“another COVID” | Some original advocacy material, but adequate specific reach/belief evidence not established here | Product- and population-specific real risks and benefits | Watch and link to real-risk explainer |

## Scope, method and interpretation rules

- Sources were checked on 14 October 2026. Publication dates, collection dates and recirculation dates are stated separately. A 2025 paper using 2019–2020 tweets is not a 2025 prevalence estimate.
- “Current” here means verified 2026 recurrence or a current relevant survey; “recent” usually means 2025. Historic examples are labeled and cannot independently establish present prominence.
- Original advocacy material establishes **what was said**, not whether it is medically correct. Technical adjudication below uses primary research, systematic evidence reviews and official scientific/regulatory material. A fact-check is used where necessary to locate an original archived example, with that limitation explicit.
- Representative surveys measure their exact questions in their sampled jurisdictions. Heard-about, true/false belief, uncertainty, willingness and uptake are different variables. Social reactions, views, article counts and search interest do not measure unique people persuaded.
- The misleading techniques named below describe observable reasoning: denominator changes, causal overreach, omitted formulation/context, anecdote-to-population extrapolation, and treating uncertainty as positive proof. They do **not** establish deceptive intent.
- Editorial priorities are an inference from prominence, harm, answerability and duplication risk. This is not a systematic review of every language or platform. Missing evidence means “not established in this search,” not “absent everywhere.”

## A. Measles/MMR: risk comparisons, vitamin A and outbreak attribution

### Exact variants to separate

1. **“Measles is harmless/beneficial; getting it is safer than vaccination.”** Most infected people survive; that true observation does not establish trivial disease burden or a favorable risk-benefit comparison. Claims about improved lifetime immunity need to include the price of acquiring infection and immune effects beyond measles itself.
2. **“Vitamin A, cod-liver oil, nutrition or ordinary treatment can replace MMR.”** This mixes a legitimate therapeutic/nutritional intervention with an unsupported substitute-for-vaccination conclusion.
3. **“The vaccine causes the outbreak; positive measles tests after vaccination prove contagious vaccine shedding.”** Vaccine-strain RNA, uncommon vaccine-associated disease, breakthrough wild-type infection and person-to-person vaccine-strain transmission are different claims.
4. **“VAERS deaths exceed measles deaths, so MMR is more dangerous.”** Raw reports after vaccination are neither adjudicated caused deaths nor comparable to disease deaths in a vaccinated population. This belongs under a shared adverse-event reporting explainer, linked from the measles article.

### Dated original examples and contemporary recurrence

- **March 2025, US-oriented English, Children's Health Defense:** Brian Hooker's two-page [MMR and measles fact sheet](https://childrenshealthdefense.org/wp-content/uploads/Measles-Fact-Sheet-2025-03.pdf) calls most cases benign, juxtaposes reported post-vaccine deaths with recent measles deaths, and frames falling historical mortality as a challenge to vaccination's benefit. It also includes vaccine-strain and autism claims. Some listed adverse effects are genuine; treating the entire sheet as a set of invented risks would be inaccurate. No independently verified circulation count was obtained.
- **22 September 2026, US-oriented English, CHD:** [“Are Routine Childhood Vaccines Deadlier Than the Diseases they Target?”](https://childrenshealthdefense.org/defender/are-routine-childhood-vaccines-deadlier-than-diseases-they-target/) bundles disease-minimization, uncertain adverse-event bounds, waning immunity, and alleged vaccine shedding. It also cites vaccine-derived polio and claims about overall health of vaccinated versus unvaccinated children. It is a useful current original artifact for several families, but one publication is not a population prevalence measure. Specific claims in this umbrella article need individual checking rather than a single verdict on its headline.
- **Attribution caution:** Kennedy's [2 March 2025 Fox op-ed](https://www.foxnews.com/opinion/robert-f-kennedy-jr-measles-outbreak-call-action-all-us) supported MMR as well as supervised vitamin A. Do not cite that op-ed as an explicit instruction to replace vaccination with vitamin A.

### Prominence and harm evidence

- **KFF, April 2025:** [Survey release](https://www.kff.org/health-information-trust/amid-growing-measles-outbreak-more-americans-are-encountering-false-claims-about-the-measles-vaccine-and-many-arent-sure-what-to-believe/), published 23 April; fielded 8–15 April, 1,380 US adults, English/Spanish online/telephone, reported sampling error about ±3 points. Prompted awareness: 33% had heard the claim that measles vaccination is more dangerous than infection; 20% had heard the vitamin-A prevention claim. Hearing a statement is not endorsing it. Vaccine delay/skipping was associated with belief in at least one tested false statement; this does not establish that exposure caused the behavior.
- **KFF, June 2026:** [Latest common-myth poll](https://www.kff.org/public-opinion/kff-tracking-poll-on-health-information-and-trust-update-on-common-vaccine-myths/), published 30 June; fielded 7–31 May among 2,480 US adults using probability address-based/cell sampling and English/Spanish interviews. Prompted awareness was 29% for measles vaccine more dangerous than infection, and 66% for MMR/autism. These questions support continuing exposure, not that 29% or 66% believe the statements. Avoid declaring a meaningful change from April 2025 without testing the survey difference.
- **Existing autism coverage:** [Annenberg's August 2026 survey](https://www.annenbergpublicpolicycenter.org/about-1-in-3-americans-say-rfk-jr-recommends-measles-vaccine/) fielded 4–17 August, probability panel n=1,904, measured 13% true, 19% unsure and 68% false for the MMR-autism proposition. This different response format must not be combined with KFF awareness or probably/definitely categories. It supports maintaining existing coverage, not a duplicate article.
- **Attention, not belief:** A [June 2026 JAMA Network Open research letter](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2849740) analyzed US Google Trends from January–June 2025. Its interrupted time-series estimated increased vitamin-A/measles and cod-liver-oil search interest around media statements. Searches cannot identify supplement use, vaccine refusal, unique individuals or causation by a particular speaker.
- **Do not exaggerate toxicity evidence:** The [poison-center notice](https://www.njpies.org/wp-content/uploads/2025/05/Poison-Centers-Observe-Increased-Vitamin-A-Exposures-in-Children-During-Measles-Outbreak-1.pdf) reported 86 pediatric vitamin-A exposures January–March 2025, up 38.7% from the corresponding 2024 period. It expressly says no increase in severity, no major effects reported in 2025, not all exposures cause illness, and some involve cosmetic retinol. This does not establish “40% more children poisoned by measles supplementation,” much less attribute cases to an individual.

### Medical assessment, real risks and contrary findings

**Disease and vaccine risk:** Measles can cause pneumonia, encephalitis and death, including in previously healthy children. [CDC clinical guidance, updated August 2026](https://www.cdc.gov/measles/hcp/clinical-overview/), supports supervised vitamin A in appropriate measles care and warns about excessive dosing. A [primary immunology study](https://pmc.ncbi.nlm.nih.gov/articles/PMC8590458/) found loss of portions of pre-existing antibody repertoires after measles. Do not translate its 11%–73% antibody-repertoire findings into “73% of everyone's immune system is destroyed.”

MMR has genuine adverse effects: fever, a small febrile-seizure risk, rare immune thrombocytopenia and rare severe allergy. [CDC's MMR safety summary](https://www.cdc.gov/vaccine-safety/vaccines/mmr.html) estimates roughly one febrile seizure per 3,000–4,000 MMR recipients; first-dose MMRV has a different seizure risk from separate MMR plus varicella. [The Pink Book](https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-13-measles.html) also recognizes measles inclusion-body encephalitis in people with demonstrated immunodeficiency. Therefore, “MMR never causes serious neurologic disease” is too broad. Product, strain, age, dose and contraindication matter. A [Cochrane review](https://www.cochrane.org/evidence/CD004407_does-measles-mumps-rubella-and-varicella-mmrv-vaccine-protect-children-and-does-it-cause-harmful) supports strong prevention and distinguishes adverse-event evidence by formulation/strain.

**Vitamin A has a real role:** A [randomized trial in hospitalized South African children](https://www.nejm.org/doi/10.1056/NEJM199007193230304) found benefit in severe measles. The [Cochrane treatment review](https://www.cochrane.org/evidence/CD001479_vitamin-measles-children), eight trials/2,574 participants, found no statistically clear mortality reduction when all studies were pooled, but benefit in a two-dose subgroup of children under two. This evidence is not a trial of replacing MMR in healthy US children.

**Contrary evidence that a fair correction must retain:** A [2022 Cochrane community-supplementation review](https://pubmed.ncbi.nlm.nih.gov/35294044/) reported lower measles incidence in two trials involving 1,982 children (RR 0.45, 95% CI 0.30–0.69; low-certainty evidence). The broad review largely concerns young children in low-/middle-income settings and nutritional deficiency. Thus, “vitamin A has never reduced measles incidence anywhere” is an overcorrection. The defensible conclusion is that these findings do not establish vitamin A as an alternative to vaccination, or routine high-dose prophylaxis for well-nourished US children. Clinical treatment, correction of deficiency and immunization can coexist.

**Outbreak source:** [October 2026 Texas whole-genome research](https://wwwnc.cdc.gov/eid/article/32/10/26-0494_article) found a closely related genotype-D8 outbreak lineage. [April 2025 outbreak surveillance](https://www.cdc.gov/mmwr/volumes/74/wr/mm7414a1.htm) similarly identified D8 in all 208 genotyped samples in the specified multistate series. These are not vaccine-strain outbreaks. A [2016 systematic review](https://pubmed.ncbi.nlm.nih.gov/27083423/) found no evidence of human-to-human measles vaccine-virus transmission in the reviewed literature. Its conclusion does not mean a vaccinated person can never acquire and transmit **wild-type** measles. Detection of vaccine RNA after immunization is not proof of contagiousness.

### Editorial boundary

Use “more dangerous” only with a defined outcome and time horizon, not a comparison of unmatched denominators. Do not attribute every pneumonia death to a single proximate cause without records; measles can contribute to secondary complications, and causal adjudication is distinct from social-media assertion. Respect patient privacy. Nutrition, appropriate antibiotics for bacterial complications, and medical care matter; that does not negate prevention.

**Harm:** avoidable infection, outbreak spread, delayed appropriate care and excessive supplement use are plausible mechanisms. The exact share of cases or poison exposures caused by a narrative is not established here. **Strength:** high for main medical corrections; high for US exposure prominence; moderate for measured attention changes; lower for causal effects of messaging.

## B. HPV: infertility, sterilization and sexual behavior

### Claim variants and original examples

- Infertility/ovarian failure after vaccination; an alleged population-control campaign; a vaccine supposedly suitable only after sexual activity; alleged encouragement of promiscuity; and “no evidence it prevents cancer.” These require separate answers.
- **Pakistan, September 2025:** [AFP's 24 October 2025 documentation](https://factcheck.afp.com/doc.afp.com.78JV7NR) locates an 18 September TikTok speech by Rashid Mehmood Soomro alleging infertility under the guise of cancer prevention. It links [archived TikTok](https://perma.cc/SR73-262B) and [YouTube](https://perma.cc/SUK3-T6NP) artifacts. The archived clip was not independently listened to in this review; exact transcription/translation remains dependent on AFP. Treat it as an attributed documented example, not a fully independently verified translated quotation. No reliable exposure count was obtained. Pakistan is the jurisdiction; do not equate this with all Urdu-, Sindhi- or English-speaking audiences.
- [UNICEF Pakistan's explanation](https://www.unicef.org/pakistan/stories/why-pakistan-needs-hpv-vaccination-safeguard-women-and-girls) independently documents infertility and sexually-active-only concerns. The [15 September 2025 launch release](https://www.unicef.org/pakistan/press-releases/pakistan-introduces-hpv-vaccine-protect-girls-cervical-cancer-joining-150-countries) establishes campaign context, not rumor prevalence.

### Distribution evidence and limits

- [WHO AIRA, Namibia, 5–11 June 2025](https://www.afro.who.int/sites/default/files/2025-06/AIRA%20Infodemic%20Trends%20Report%2005-11%20June%202025.pdf): the selected HPV discussion included three posts, 893 reactions, 437 comments and 40 shares/retweets. It describes a parliamentary intervention involving consent/education concerns and infertility assertions. Consent and outreach questions are legitimate; do not categorize all comments as misinformation or sum metrics into people reached.
- [WHO AIRA, Ghana, 19–25 June 2025](https://www.afro.who.int/sites/default/files/2025-07/AIRA%20Infodemic%20Trends%20Report%2019-25%20%20June%202025%20%20%20%281%29.pdf): ten selected posts, 2,915 reactions and 33 shares. Themes included infertility, unknown adverse effects, experimentation, practical access questions and favorable reactions. These totals cover the selected conversation, not only false posts; the report explicitly disclaims representativeness. Search was multilingual; the report's English language is not a language breakdown of the audience.
- **Current recurrence:** [WHO Sierra Leone, 28 May 2026](https://www.afro.who.int/countries/sierra-leone/news/community-voices-help-boost-hpv-vaccine-uptake-during-african-vaccination-week-kailahun-district) describes infertility rumors, refusal and school absence during the 2026 campaign. This is a local program account, not a controlled evaluation or national survey. Its vaccination-after-dialogue figures do not identify the causal effect of communication.
- [JMIR, 12 May 2025](https://www.jmir.org/2025/1/e54657/) studied 263 US caregivers recruited through Qualtrics in **April 2022**, judging tweets collected **December 2019–April 2020**. Infertility messages elicited concern; this is susceptibility/content evidence, not a representative 2025–2026 belief estimate. A different [2025 Japan paper](https://www.jmir.org/2025/1/e68881/) likewise uses historical tweets. Avoid laundering publication date into current prevalence.

### Independent scientific assessment and uncertainties

- The [2025 Cochrane program-effects review](https://www.cochrane.org/evidence/CD015363_what-are-benefits-and-risks-different-human-papillomavirus-hpv-vaccines-preventing-cervical-cancer), searching through September 2024, included 225 studies and over 132 million participants. It found moderate-certainty evidence of lower cervical-cancer incidence, with about 80% relative reduction for vaccination at or before age 16. The technical abstract rates evidence against increased infertility, premature ovarian failure and sexual activity as **moderate**, not absolute proof of zero risk. GBS evidence is **low** certainty in that abstract, despite looser wording in the plain-language summary. Do not use the strongest wording from a press release when the technical assessment is more qualified.
- [Danish nationwide cohort, JAMA Network Open 2021](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783512): 996,300 girls/women, 144 primary-ovarian-insufficiency diagnoses, adjusted HR 0.96 (95% CI 0.55–1.68). This found no association, but the authors explicitly say a clinically relevant increase cannot be excluded given rarity. The confidence interval must not be described as proof of identical risks. The combined evidence is more informative than this study alone.
- [WHO GACVS infertility review](https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/human-papillomavirus-vaccines/infertility), published January 2020 after its December 2019 review, considered case reports and epidemiology, including a retracted pregnancy analysis. Cases following vaccination justify investigation, but timing alone does not establish vaccine-caused infertility. Pregnancy rates are not interchangeable with biological fertility.
- [Ontario quasi-experimental cohort](https://pubmed.ncbi.nlm.nih.gov/25487660/), 260,493 girls, used program eligibility and regression discontinuity; vaccination did not increase the measured pregnancy/non-HPV-STI outcomes. Those are clinical proxies for sexual behavior, not exhaustive observations of every sexual decision. This is a useful answer to “promiscuity,” without moralizing.

### Real risks, scope and placement

Recognize pain, short-lived systemic reactions, fainting with injury potential and very rare severe allergic reactions, as described in [CDC's HPV safety review](https://www.cdc.gov/vaccine-safety/vaccines/hpv.html). Keep products and schedules explicit. A preventive vaccine does not treat an established HPV infection or remove the need for cervical screening. Cancer protection is now supported by long-term outcome data, but effectiveness is not 100% and evidence is stronger for cervical outcomes than every HPV-associated cancer.

**Misleading mechanisms:** temporal anecdotes substituted for comparisons; infertility/sexuality conflation; portraying program age targeting as evidence of sexual intent; presenting remaining uncertainty as evidence of sterilization. **Legitimate disputes:** consent, inclusion of boys, financing, access, one- versus two-dose schedules, and screening policy. **Harm:** missed opportunities for cancer prevention, with downstream burden occurring over years. Do not infer how many cancers a particular rumor caused.

**Recommendation:** one fertility/cancer-prevention page with behavior as a section. Recent multi-country recurrence supports relevance, but quantify prominence only within the monitored settings. Do not create a separate “promiscuity” page without stronger recent prominence evidence.

## C. Hepatitis B: “Babies don't have sex, so they don't need it”

### Original claim and prominence

**22 September 2025, United States, English:** Trump's public announcement described HBV as sexually transmitted and said babies need not receive the vaccine, proposing waiting until about age 12. A [recorded Newsweek clip](https://www.youtube.com/watch?v=9Z-Vow_uTgc) and the timestamped transcript reproduced in a [24 September court filing, approximately page 25](https://childrenshealthdefense.org/wp-content/uploads/a22b0f53-8e99-f011-b4cb-001dd80b197d.pdf) provide the original statement and context. The filing host is not the scientific authority; it is a source for the reproduced speech. Do not convert this high-profile platform into a measured audience or false-belief prevalence estimate.

The closest representative measure located is [Annenberg, published 5 December 2025](https://www.annenbergpublicpolicycenter.org/although-public-overwhelmingly-supports-hepatitis-b-vaccine-for-a-newborn-partisan-differences-exist/), fielded 17 November–1 December among 1,637 US adults. After a preamble stating the CDC recommendation, 77% said they would likely recommend vaccination to someone with a newborn. Asked youngest age, 35% chose birth and 16% one month; 40% identified liver protection, 32% were unsure. These measure recommendation/knowledge after particular wording, **not** belief that babies cannot catch HBV. No representative estimate of that exact misconception was found.

### Medical facts and limits

HBV can be transmitted during childbirth and through infected blood/body-fluid exposure; sex and injecting-drug exposure are not the only routes. A negative maternal test reduces the identified perinatal risk but does not make every future exposure impossible or eliminate screening/documentation errors. Early-life infection has a much greater probability of becoming chronic than adult infection. The [2018 ACIP evidence/recommendation report](https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm) explains the birth dose as a safety net against missed maternal infection and early household exposure. Do not imply transmission through ordinary social contact or that every infant has the same absolute risk.

**Primary benefit evidence:** The [Qidong cluster-randomized trial's 30-year follow-up](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001774), published 2014, assigned 39,292 newborns to neonatal vaccination and 34,441 to control in high-endemicity China. It reported reduced primary liver cancer and other liver outcomes. Important limitations include few cancer events, losses to follow-up and incomplete serum follow-up. Controls received neither vaccine nor placebo initially; many later received catch-up vaccination. This is strong evidence for early-life HBV prevention, not a direct randomized comparison of birth versus two months among infants of reliably screened negative US mothers.

**Primary safety evidence:** A [Vaccine Safety Datalink study](https://pubmed.ncbi.nlm.nih.gov/15247605/) of over 350,000 California births from 1993–1998 found no association between birth immunization and neonatal death after cause review. Vaccinated and unvaccinated infants differ clinically, and the striking crude difference is not proof that vaccination prevents all-cause neonatal death. [CDC's safety review](https://www.cdc.gov/vaccine-safety/vaccines/hepatitis-b.html) links neonatal and longer-term studies. Common reactions are local pain and short-lived systemic symptoms; severe allergy is rare. The [Pink Book](https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-10-hepatitis-b.html) gives an estimated anaphylaxis rate around 1.1 per million doses. That book contains some outdated product recommendations, so use it for the specified safety datum, not current scheduling.

### Critical policy dating: current as of this report

The [current CDC main child schedule](https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html) states that the **16 March 2026 court order stayed June, September and December 2025 ACIP votes and the 5 January 2026 decision memo**, leaving the July 2, 2025 schedule current. The [December 16, 2025 CDC fact sheet](https://www.cdc.gov/media/releases/2025/fact-sheet-hepatitis-b-immunization.html), still online, described individual decision-making for babies of negative mothers; it must not be represented as the operative current schedule without acknowledging the stay. A court order determines operative policy here, not the biological truth of a vaccine claim.

[AAP's July 2026 resource](https://www.aap.org/en/patient-care/hepatitis-b) continues to support the birth dose. [WHO](https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-B/) recommends an early birth dose globally. **Jurisdiction matters:** [England's routine infant program](https://www.gov.uk/government/publications/a-guide-to-immunisations-for-babies-up-to-13-months-of-age/a-guide-to-immunisation-for-babies-up-to-13-months-of-age-for-children-born-on-or-after-1-july-2024) starts the routine combined series later, alongside a [targeted birth-dose pathway for exposed babies](https://www.gov.uk/government/publications/protecting-your-baby-against-hepatitis-b-leaflet/protecting-your-baby-against-hepatitis-b-with-the-hepatitis-b-vaccine). Different programs do not imply agreement that infants cannot acquire infection. Birth-weight and maternal-status exceptions also prevent a simplistic “every baby, identical timing” rule.

**Boundary:** advocating a targeted policy is a recommendation dispute; asserting no nonsexual infant transmission is false. A family preference or concern is not itself a factual claim. “Wait until 12 because no prior risk” combines a policy preference with an incorrect premise. Do not label all alternatives to US universal birth dosing misinformation.

**Harm:** missed perinatal prophylaxis is time-sensitive; later vaccination cannot undo an already established infection. **Confidence:** high medical adjudication, high verification of the public example, insufficient exact belief prevalence. **Recommendation:** standalone focused on transmission and rationale, with a clearly dated policy box; link autism/ingredients elsewhere.

## D. Influenza: infection mechanism, variable effectiveness and the Cleveland result

### Separate three claims

1. A flu injection contains infectious influenza that gives you flu.
2. Fever/aches or a respiratory illness after vaccination proves vaccine-caused influenza.
3. A study showing more detected infections among vaccinated employees proves flu vaccines generally cause infection, damage immunity or have no benefit.

The first is a mechanism claim; the second confuses temporal sequence and diagnosis; the third overextends an empirical association. None is answered well by simply saying vaccines work.

### Original examples and prominence

- [CHD, 8 April 2025](https://childrenshealthdefense.org/defender/flu-shots-27-percent-higher-risk-influenza-2024-2025-season/), presents the Cleveland Clinic finding as vaccination having led to 27% greater risk and draws broader implications. This is an actual negative observational estimate, not an invented number. Its causal/general claims require separate adjudication. No audited reach count was found.
- [NZDSOS, 18 September 2026](https://nzdsos.com/2026/09/18/professor-michael-bakers-flu-vaccine-claims-the-evidence-he-isnt-discussing/), English, New Zealand-oriented, reuses the 27% result. Some criticisms, such as asking for absolute benefit and scrutinizing observational cardiovascular claims, are legitimate. Other arguments conflate endpoints and infer broader immune injury. The article's pediatric discussion moves from numbers needed to prevent **hospitalization** to wording about preventing **infection**; those are not interchangeable. This establishes recurrence, not national reach or belief.
- **Historical representative baseline:** [Annenberg, February 2023](https://www.annenbergpublicpolicycenter.org/flu-vaccination-rate-holds-steady-but-misinformation-about-flu-and-covid-persists/), fielded 10–16 January among 1,657 US adults, found 29% thought people could get flu from the shot and 16% unsure. It also found 15% agreed breakthrough infections mean shots do not work. These figures are dated 2023, not current estimates.
- **Recent narrower context:** [Vanderbilt's Tennessee Child Health Poll, March 2025](https://news.vumc.org/2025/03/04/poll-parents-report-challenges-accessing-care-concerns-about-influenza-and-hpv-vaccines/) reported concerns about safety and illness among parents reluctant to vaccinate. “May cause illness” includes genuine side effects and cannot all be coded as false belief. State parents are not a national adult sample.
- [NFID/NORC's 2026 respiratory survey](https://www.nfid.org/resource/2026-national-survey-on-respiratory-diseases/), probability sample n=1,206, 13–17 August, English online/phone, documents knowledge and access barriers. It is useful contrary context: nonvaccination is not synonymous with misinformation. Do not recode recommendation uncertainty or inability to obtain a dose as anti-vaccine belief.

### What the Cleveland study actually shows

The [4 April 2025 preprint version](https://www.medrxiv.org/content/10.1101/2025.01.30.25321421v3/) followed 53,402 Ohio employees during the 2024–2025 season and reported adjusted HR 1.27 (95% CI 1.07–1.51) for detected influenza. The [11 October 2025 revision](https://www.medrxiv.org/content/10.1101/2025.01.30.25321421v4) extended follow-up and stratified by epidemic activity; the high-activity estimate remained above one. The repository still labels it a preprint, although its revision notes discuss peer-review responses. No confirmed journal publication was established in this review.

This is a real, unfavorable result for the measured setting/outcome. It does not randomize vaccination, fully measure prior infection/immunity or ascertain every infection irrespective of testing. The revised version discusses testing, so the simplistic criticism that the authors ignored it entirely is unsuitable. Residual confounding, selection and season-specific biology are competing explanations, not automatically proven explanations. It cannot by itself establish effects on hospitalization/death or universal effects in other populations/seasons. Unequal vaccinated/unvaccinated group size alone does not invalidate a study.

### Contrasting primary evidence and real risks

- [Four US networks, 2024–2025 interim estimates](https://www.cdc.gov/mmwr/volumes/74/wr/mm7406a2.htm), published February 2025, found positive adjusted effectiveness against medically attended influenza and hospitalization, with variation by age/network. This is not the same population or endpoint as the employee cohort, and the observational design retains confounding limitations.
- [Three US networks, 2025–2026 interim estimates](https://www.cdc.gov/mmwr/volumes/75/wr/mm7509a2.htm), March 2026, estimated adult effectiveness of 22%–34% against outpatient visits and 30% against hospitalization; pediatric estimates were 38%–41% and 41%, respectively. Some age/subtype estimates were imprecise or not statistically significant. These findings support partial benefit, not a guaranteed or uniform effect. Antigenic mismatch and changing strains can reduce effectiveness.
- [CDC influenza safety guidance](https://www.cdc.gov/flu/hcp/vax-summary/vaccine-safety.html) acknowledges common reactions, formulation-specific contraindications and rare GBS risk. [Ontario self-controlled research](https://pubmed.ncbi.nlm.nih.gov/23810252/) estimated attributable GBS risk of 1.03 per million vaccinations versus 17.2 per million **influenza-coded health-care encounters**. The latter is not a per-infection denominator for all community flu and should be labeled exactly.
- **Current product update:** [FDA approved MFLUSIVA on 5 August 2026](https://www.fda.gov/vaccines-blood-biologics/vaccines/mflusiva), an mRNA influenza vaccine for age 50+. Therefore, “all flu shots are killed-virus or recombinant-protein vaccines” is now outdated. Specify the product: conventional inactivated, recombinant and mRNA injections do not deliver replicating influenza virus; nasal live-attenuated vaccine is a different formulation with different eligibility. Do not transfer all product-specific reactogenicity/risk estimates between technologies.

**Boundary:** recommendations for healthy adults versus risk groups, annual mandates and absolute-benefit thresholds are policy questions. Acknowledging imperfect effectiveness is correct. Claiming that breakthrough disease proves zero benefit is not. “I felt unwell afterward” is a report of experience, not automatically an incorrect diagnosis or dishonesty.

**Harm:** foregoing potentially beneficial protection, particularly against severe outcomes; unsupported generalization from one season or outcome. **Confidence:** high on mechanism; moderate/high for population-level benefit with season-specific uncertainty; insufficient current representative prevalence for the precise negative-effectiveness narrative. **Recommendation:** consolidated explanation, with the Cleveland result prominently and fairly addressed rather than hidden in a footnote.

## E. Polio: a true vaccine risk used without formulation and setting

### Claims, current examples and distribution

The defensible factual proposition is that **live oral polio vaccines can rarely cause vaccine-associated paralytic polio, and their descendants can circulate and cause outbreaks**. The misleading extensions are that all polio vaccines do this, that the injectable vaccine caused an identified vaccine-derived case, that every current case worldwide is vaccine-caused, or that vaccine-derived outbreaks establish vaccination had no benefit.

- [UNICEF-managed Polio Pulse, 8 September 2025](https://poliokit.org/pulse/mutation-accusation-how-cvdpv-headlines-are-fueling-claim-vaccine-itself-causes-polio) documents reuse of cVDPV headlines across platforms and countries. Its monitoring covers 12 major languages in selected polio-endemic/outbreak geographies; no language-specific numerator, reach estimate or representative belief denominator is supplied for this item. Its “high risk” designation is the monitor's assessment, not a measured population rate.
- [WHO AIRA, cover-dated 15–31 March 2026, published April](https://www.afro.who.int/sites/default/files/2026-04/Report%20.pdf), documents campaign-related suspicions in Nigeria, Malawi and Ethiopia alongside legitimate delivery/consent concerns. Its 239 articles and 181 article interactions are **topic-monitoring totals**, not 239 false posts or 181 believers. There are inconsistent internal date labels, so cite cover/method period and disclose this quality-control issue before using trend comparisons. The report explicitly limits representativeness.
- The September 2026 CHD umbrella artifact above invokes recent US vaccine-derived cases while arguing that risks outweigh disease burden. The US statement about vaccine-derived cases is not inherently false. The necessary missing context is **which vaccine, where the ancestral oral dose was given, and whether the affected person was vaccinated**. There is no independently verified audience count for the article.

### Primary scientific adjudication

[WHO's polio Q&A](https://www.who.int/news-room/questions-and-answers/item/poliomyelitis) distinguishes oral and inactivated formulations and estimates vaccine-associated paralytic polio at roughly one per 2.7 million oral doses. That is a broad average, not a uniform individual risk or an outbreak case rate. IPV cannot cause poliovirus infection. OPV generates intestinal immunity important for interrupting transmission; the vaccines have different strengths.

**VAPP and cVDPV are not synonyms.** VAPP is rare vaccine-associated paralysis in a recipient/contact. cVDPV refers to vaccine-descended virus that has evolved and circulates, usually where immunity gaps permit sustained transmission. An unvaccinated person can contract such virus. Low coverage can reflect access failures, conflict and weak campaigns as well as refusal; blaming all outbreaks on uninformed parents is unsupported.

[The 2022 New York primary investigation](https://www.cdc.gov/mmwr/volumes/71/wr/mm7133e2.htm) identified paralytic vaccine-derived type-2 infection in an unvaccinated adult and genetically related wastewater detections. It did not show that the US injectable vaccine generated the virus. Distinguish importation/transmission from manufacture or administration locally.

**Do not minimize program limitations:** [Primary 2023 surveillance](https://www.cdc.gov/mmwr/volumes/72/wr/mm7238a4.htm) documented emergences linked to novel oral type-2 vaccine. nOPV2 is designed to be more genetically stable, not to have zero seeding risk. [GPEI's OPV-cessation discussion](https://polioeradication.org/who-we-are/sustaining-a-polio-free-world/opv-cessation/) acknowledges the need eventually to stop oral vaccine use and lessons from the 2016 switch. Those are real policy and implementation problems. They do not erase the large fall in wild poliomyelitis or imply that leaving populations susceptible stops transmission.

[WHO's March 2026 emergency-committee statement](https://www.who.int/news/item/04-03-2026-statement-of-the-forty-fourth-meeting-of-the-polio-ihr-emergency-committee) provides current outbreak/program context. When comparing wild-virus and vaccine-derived counts, use the same reporting period, case definition and data cutoff. “More vaccine-derived than wild cases in year X” can be true after successful suppression of wild virus; the count ratio alone is not a counterfactual estimate of cases without vaccination.

### Historical variants and editorial boundary

SV40 contamination and the 1955 Cutter manufacturing failure were real historical events. They should not be dismissed as imaginary, but do not establish contamination or the same manufacturing risk in current IPV. This review did not establish a sufficiently complete original-claim/modern-prominence/scientific-source chain to recommend separate SV40, DDT or sanitation pages. Keep them as watch items or link to a shared historical-risk explainer. Avoid relying on a resurfaced video date as the date of the original statement.

**Misleading mechanisms:** formulation conflation, denominator neglect, treating a residual eradication problem as the whole history, and moving from a historical manufacturing error to a present product claim. **Legitimate questions:** choice of OPV/IPV, outbreak strategies, timing of OPV withdrawal, campaign quality, consent, equitable delivery and adverse-event support.

**Harm:** refusal can widen immunity gaps; simplistic denial of genuine OPV harms can also damage trust. **Confidence:** high medical distinction; moderate evidence of recurring monitored narratives; no global belief estimate. **Recommendation:** a question-led, nuanced standalone only if not already covered, with a visible “yes, some oral vaccines can; IPV cannot” answer and a dated geography box.

## F. RSV and other candidates: retain proportionate coverage

A vaccine being new or a regulator investigating a signal does not establish widespread misinformation. Conversely, a warning should not be treated as merely a rumor.

- [FDA's 7 January 2025 safety communication](https://www.fda.gov/safety/medical-product-safety-information/fda-requires-guillain-barre-syndrome-gbs-warning-prescribing-information-rsv-vaccines-abrysvo-and) required GBS warnings for Abrysvo and Arexvy based on postmarketing observational evidence. Present the product, studied age group and risk window when discussing the underlying studies; do not imply the same risk has been demonstrated in infants receiving a different intervention.
- Infants can receive preventive monoclonal antibodies, such as nirsevimab; these are not vaccines. Maternal Abrysvo, older-adult RSV vaccines and infant antibodies have different evidence and eligibility. [A November 2025 US multicenter case-control analysis](https://www.cdc.gov/mmwr/volumes/74/wr/mm7437a1.htm) estimated nirsevimab effectiveness against infant RSV ICU admission at 80% (95% CI 70%–86%). That is a particular observational severe-outcome estimate, not a universal guarantee or proof of zero adverse effects.
- The 2026 NFID survey above measured RSV knowledge and access, not prevalence of a specific sterilization/death claim. Current original advocacy articles can be monitored, but this review did not establish enough exact-claim reach/belief evidence for a high-priority standalone debunk.

**Decision:** a short “real risks and different products” section or watch entry is defensible. Do not manufacture symmetry by giving RSV the same page priority as measles or HPV. This task likewise does not establish a standalone case for every routine vaccine, including rotavirus, varicella, pneumococcal or tetanus vaccination. Their omission is an editorial prioritization, not a safety or importance judgment.

## Cross-cutting editorial safeguards and remaining gaps

1. **Compare like with like.** Distinguish infection, symptomatic illness, health-care visits, hospitalization, disability and death. State person-, dose-, case- or encounter-denominators. Relative risk is not absolute risk. A confidence-limit bound is not an observed harm rate.
2. **Separate public controversy from evidence.** Policy changes, court orders, lawsuits and compensation do not independently establish biological causation. A changing recommendation can reflect values, epidemiology or governance; do not fact-check preferences as if they were laboratory results.
3. **State real harms early.** Febrile seizures, rare allergy, OPV-associated paralysis and RSV GBS warnings belong in the main explanation, with appropriate population/product scope. “Safe” should mean a favorable evidence-based risk-benefit profile for the specified indication, not impossible to harm.
4. **Avoid inflated prominence.** This review's strongest representative exact-claim evidence is US measles and historical US influenza. HPV/polio prominence is predominantly selected monitoring plus campaign accounts. HBV has high-profile original speech and recommendation polling, but no exact false-belief prevalence. No valid global ranking by prevalence can be produced from these inputs.
5. **Do not infer all nonvaccination is misinformation.** Access, cost, schedules, medical contraindications, trusted-care availability, logistics and preferences matter. Country and language are not interchangeable categories.
6. **Do not overcorrect the strongest contrary evidence.** Retain vitamin A's nutritional/treatment evidence; the Cleveland negative association; the wide Danish ovarian-insufficiency interval; genuine OPV risks; and the current RSV warning. Explain why these do or do not support the broader claim.
7. **Duplication:** existing autism/MMR pages should own the autism proposition. Shared pages should own VAERS interpretation, ingredients, placebo/clinical-trial design, historical disease decline and vaccinated-versus-unvaccinated observational comparisons. Vaccine-specific articles should use compact applications and links rather than repeating every dispute.
8. **Before drafting/publishing:** independently transcribe any non-English original clip to be quoted; confirm current labels/schedules; recheck the precise clinical endpoint and source version for every number; resolve the AIRA March/April date inconsistency if making a trend claim; and inspect the site's existing page inventory. These are QA steps, not reasons to delay the established corrections.

### Suggested compact writing briefs

- **Measles update:** “Measles can be serious. Vitamin A has a treatment role, but is not a substitute for vaccination.” Include the nutritional-evidence qualification and real MMR risks.
- **HPV standalone:** “Does HPV vaccination affect fertility?” Lead with population evidence, acknowledge rare-outcome uncertainty, then explain cancer prevention and why vaccination precedes exposure.
- **HBV standalone:** “Why do newborns receive hepatitis B vaccine?” Explain transmission first, risk of chronic infection second, policy differences third. Date the US policy box.
- **Flu page/section:** “Can a flu shot give you flu, and why do studies disagree on effectiveness?” Keep the infection mechanism and comparative-effectiveness questions separate.
- **Polio conditional standalone:** “Can polio vaccines cause polio?” Use a formulation comparison and explain both direct rare harms and circulating descendants. Avoid a false/true badge without qualifications.
- **RSV watch:** “Which RSV product, which population, which risk?” Escalate only when a precise recurring false claim has independently documented current prominence.